# Study Describing the Immunogenicity and Safety of Quadrivalent Recombinant Influenza Vaccine (RIV4) Versus a Licensed Quadrivalent-inactivated Influenza Vaccine (IIV4) (Fluarix® Quadrivalent) in Participants 18 Years of Age and Older in South Korea

> **NCT05144945** · PHASE3 · COMPLETED · sponsor: **Sanofi Pasteur, a Sanofi Company** · enrollment: 301 (actual)

## Conditions studied

- Influenza (Healthy Volunteers)

## Interventions

- **BIOLOGICAL:** Quadrivalent Recombinant Influenza Vaccine (RIV4)
- **BIOLOGICAL:** Quadrivalent inactivated influenza vaccine (IIV4)

## Key facts

- **NCT ID:** NCT05144945
- **Lead sponsor:** Sanofi Pasteur, a Sanofi Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-12-07
- **Primary completion:** 2022-09-01
- **Final completion:** 2022-09-01
- **Target enrollment:** 301 (ACTUAL)
- **Last updated:** 2025-09-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05144945

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05144945, "Study Describing the Immunogenicity and Safety of Quadrivalent Recombinant Influenza Vaccine (RIV4) Versus a Licensed Quadrivalent-inactivated Influenza Vaccine (IIV4) (Fluarix® Quadrivalent) in Participants 18 Years of Age and Older in South Korea". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05144945. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*